Immunology News and Research

Latest Immunology News and Research

Study reveals genomic switches separate autoimmune disorders in different clusters

Genomic switches can predispose an individual to one set of autoimmune disorders but protect the same person against another set of them, scientists at Stanford University School of Medicine have found.

24 Dec 2009

Comprehensive review of cell migration

Cell migration is a highly complex process which involves several compartments of the cell, including surface receptors, signalling elements and the cytoskeleton.

23 Dec 2009

Researchers mix active drug and placebo to maximize drug benefits for efficient treatment

Researchers used the placebo effect to successfully treat psoriasis patients with one quarter to one half of their usual dose of a widely used steroid medication, according to an early study published online today in the journal Psychosomatic Medicine.

23 Dec 2009

Researchers develop new approach for treating and healing skin abscesses

Researchers at the Albert Einstein College of Medicine of Yeshiva University have developed a new approach for treating and healing skin abscesses caused by bacteria resistant to most antibiotics.

23 Dec 2009

Australian scientists show connections between brain and regulation of bone mass

The brain acts as a profound regulatory centre, controlling myriad processes throughout the body in ways we are only just beginning to understand. In new findings, Australian scientists have shown surprising connections between the brain and regulation of bone mass.

23 Dec 2009

LA BioMed physician-researchers named Super Doctors in the Los Angeles Magazine

Los Angeles Magazine, in its January issue, will name 37 of the physician-researchers at Los Angeles Biomedical Research Institute (LA BioMed) to be among Southern California Super Doctors.

22 Dec 2009

Olive oil for prevention of breast cancer

Ana Ripoll, Rector of Universitat Aut-noma de Barcelona (UAB), and Pedro Barato, President of "Organizaci-n Interprofesional del Aceite de Oliva Espa-ol", signed a research agreement to carry out an in depth study on how the intake of olive oil can work towards preventing and fighting against breast cancer.

22 Dec 2009

QLT Ophthalmics to distribute Visudyne in the U.S. market

QLT Inc. ("QLT" or the "Company") is pleased to announce the establishment of its commercial presence in the United States through a newly formed U.S. subsidiary, QLT Ophthalmics, Inc. ("QOI"). QOI will take on the sales and marketing of Visudyne(R) in the U.S.

22 Dec 2009

TB bacterium does not contain genes needed for spore formation

But a new study by researchers at Loyola University Health System and other centers casts doubt on the TB spore theory. Researchers were unable to detect spores in TB cultures and demonstrated that the TB bacterium doesn't even contain genes related to those needed to produce spores. Researchers also failed to find any spores in frogs infected with TB bacteria, which would have been expected if TB bacteria produced spores in the course of infection.

22 Dec 2009

Rifampicin resistant tuberculosis

Scientists have identified a strain of antibiotic-resistant tuberculosis that thrives in the presence of rifampin, a front-line drug in the treatment of tuberculosis. The bacterium was identified in a patient in China and is described in a study by researchers at the Johns Hopkins Bloomberg School of Public Health, Chongqing Pulmonary Hospital, Lanzhou University and Fudan University.

22 Dec 2009

Findings may help develop new antiviral drugs for influenza

Investigators at Burnham Institute for Medical Research (Burnham), Mount Sinai School of Medicine (Mount Sinai), the Salk Institute for Biological Studies (Salk) and the Genomics Institute of the Novartis Research Foundation (GNF) have identified 295 human cell factors that influenza A strains must harness to infect a cell, including the currently circulating swine-origin H1N1.

22 Dec 2009

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

Idera Pharmaceuticals, Inc. today announced positive interim results from a Phase 1 clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection (HCV). IMO-2125 is an agonist of Toll-like Receptor 9 that Idera designed to treat HCV by inducing endogenous interferon-alpha and other Th1-type cytokines and chemokines.

21 Dec 2009

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that they have entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.

18 Dec 2009

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., announced today that it has obtained exclusive rights from the California Institute of Technology to inventions made in the laboratory of David Baltimore, Ph.D. covering methods and compositions for modulating microRNA-146 and microRNA-155.

18 Dec 2009

Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences

Amarillo Biosciences, Inc. (ABI) today announced that its ongoing study of oral interferon as prevention/treatment of influenza and other respiratory illnesses in Perth, Australia is nearing completion.

17 Dec 2009

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

Researchers from the La Jolla Institute for Allergy & Immunology will take aim at several of the world's most dangerous infectious diseases - tuberculosis, malaria and dengue virus -- in a five-year, $18.8 million federally-funded set of projects seeking to make new inroads toward vaccines against the disorders.

17 Dec 2009

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).

17 Dec 2009

Promising breakthrough in adjuvant development may lead to cost-effective therapeutic vaccines

It should be possible to use therapeutic vaccines to create both cheap and effective drugs for diseases like cancer and allergies. One problem in developing such vaccines has previously been the lack of adjuvants, substances that make vaccines more effective. However, there has now been a major breakthrough in this area. The study, led by Swedish scientists at Uppsala University, is published in the December issue of the journal Vaccine.

17 Dec 2009

New study shows how stem cell activity can contribute to cancer

In a developing animal, stem cells proliferate and differentiate to form the organs needed for life. A new study shows how a crucial step in this process happens and how a reversal of that step contributes to cancer.

17 Dec 2009

People are more prone to Crohn's disease and ulcerative colitis, explains new research

New research by the University of Adelaide could help explain why some people are more prone to Crohn's disease, ulcerative colitis and other autoimmune diseases.

17 Dec 2009

Immunology News and Research

Latest Immunology News and Research

Study reveals genomic switches separate autoimmune disorders in different clusters

Comprehensive review of cell migration

Researchers mix active drug and placebo to maximize drug benefits for efficient treatment

Researchers develop new approach for treating and healing skin abscesses

Australian scientists show connections between brain and regulation of bone mass

LA BioMed physician-researchers named Super Doctors in the Los Angeles Magazine

Olive oil for prevention of breast cancer

QLT Ophthalmics to distribute Visudyne in the U.S. market

TB bacterium does not contain genes needed for spore formation

Rifampicin resistant tuberculosis

Findings may help develop new antiviral drugs for influenza

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

Promising breakthrough in adjuvant development may lead to cost-effective therapeutic vaccines

New study shows how stem cell activity can contribute to cancer

People are more prone to Crohn's disease and ulcerative colitis, explains new research

Immunology eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology